This company listing is no longer active
Cyclacel Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Cyclacel Pharmaceuticals's earnings have been declining at an average annual rate of -27.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 22% per year.
Key information
-27.6%
Earnings growth rate
46.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 22.0% |
| Return on equity | -574.9% |
| Net Margin | -6,402.1% |
| Next Earnings Update | 19 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cyclacel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -25 | 7 | 22 |
| 30 Jun 23 | 0 | -24 | 7 | 22 |
| 31 Mar 23 | 0 | -23 | 7 | 21 |
| 31 Dec 22 | 0 | -21 | 7 | 20 |
| 30 Sep 22 | 0 | -19 | 7 | 18 |
| 30 Jun 22 | 0 | -19 | 7 | 18 |
| 31 Mar 22 | 0 | -20 | 7 | 18 |
| 31 Dec 21 | 0 | -19 | 7 | 15 |
| 30 Sep 21 | 0 | -20 | 7 | 16 |
| 30 Jun 21 | 0 | -18 | 7 | 11 |
| 31 Mar 21 | 0 | -15 | 6 | 7 |
| 31 Dec 20 | 0 | -12 | 6 | 5 |
| 30 Sep 20 | 0 | -8 | 5 | 0 |
| 30 Jun 20 | 0 | -8 | 5 | 0 |
| 31 Mar 20 | 0 | -7 | 5 | 0 |
| 31 Dec 19 | 0 | -8 | 5 | 0 |
| 30 Sep 19 | 0 | -8 | 5 | 0 |
| 30 Jun 19 | 0 | -8 | 5 | 0 |
| 31 Mar 19 | 0 | -8 | 5 | 0 |
| 31 Dec 18 | 0 | -7 | 5 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -14 | 5 | 0 |
| 31 Mar 18 | 0 | -15 | 5 | 0 |
| 31 Dec 17 | 0 | -15 | 5 | 0 |
| 30 Sep 17 | 0 | -16 | 5 | 0 |
| 30 Jun 17 | 0 | -10 | 5 | 0 |
| 31 Mar 17 | 1 | -11 | 6 | 0 |
| 31 Dec 16 | 1 | -12 | 6 | 0 |
| 30 Sep 16 | 1 | -13 | 6 | 0 |
| 30 Jun 16 | 1 | -12 | 6 | 0 |
| 31 Mar 16 | 2 | -13 | 6 | 0 |
| 31 Dec 15 | 2 | -15 | 6 | 0 |
| 30 Sep 15 | 2 | -16 | 6 | 0 |
| 30 Jun 15 | 2 | -18 | 6 | 0 |
| 31 Mar 15 | 2 | -20 | 6 | 0 |
| 31 Dec 14 | 2 | -20 | 6 | 0 |
| 30 Sep 14 | 2 | -18 | 6 | 0 |
| 30 Jun 14 | 1 | -19 | 6 | 0 |
| 31 Mar 14 | 1 | -13 | 7 | 0 |
| 31 Dec 13 | 1 | -20 | 8 | 0 |
| 30 Sep 13 | 1 | -21 | 9 | 0 |
| 30 Jun 13 | 1 | -18 | 9 | 0 |
| 31 Mar 13 | 0 | -23 | 9 | 0 |
Quality Earnings: UXI is currently unprofitable.
Growing Profit Margin: UXI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UXI is unprofitable, and losses have increased over the past 5 years at a rate of 27.6% per year.
Accelerating Growth: Unable to compare UXI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: UXI has a negative Return on Equity (-574.89%), as it is currently unprofitable.